Topoisomerase II inhibitor 23
Topoisomerase II inhibitor 23 is a potent topoisomerase II inhibitor (IC50 = 0.94 μM). Topoisomerase II inhibitor 23 shows high selectivity and exceptional cytotoxic activity in MCF-7, HepG2, and HCT116 cells. Topoisomerase II inhibitor 23 induces cell cycle arrest at the G1 phase, leading to inhibition of cell proliferation. Topoisomerase II inhibitor 2 induces apoptosis by up-regulating the pro-apoptotic Bax level and down-regulating the anti-apoptotic Bcl-2 level.
For research use only. We do not sell to patients.
- Formula: C28H23BrN2O2S
- Molecular Weight:531.46
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Topoisomerase Isoforms
More
Biological Activity
Description
In Vitro
Topoisomerase II inhibitor 23 (Compound, IId) shows exceptional cytotoxic activity against MCF-7 (IC50 = 24.52 μM), HepG2 (IC50 = 28.92 μM), and HCT116 cells (IC50 = 54.38 μM)[1].
Topoisomerase II inhibitor 23 shows high selectivity towards MCF-7 cells, HepG2 and HCT116 cells with SI of 3.8. 3.3 and 1.7 on the human cell line BJ cell[1].
Topoisomerase II inhibitor 23 (24.52 μM, 24 h) exhibits cell growth arrest at the G1 phase, leading to inhibition of cell proliferation in MCF-7 cells[1].
Topoisomerase II inhibitor 23 (24.52 μM, 24 h) induces apoptosis by up-regulating the pro-apoptotic Bax level and down-regulating the anti-apoptotic Bcl-2 level in MCF-7 cells[1].
Topoisomerase II inhibitor 23 shows potent topoisomerase II inhibitory activity (IC50 = 0.94 μM), higher than that of Doxorubicin (HY-15142A) (IC50 = 3.08 μM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF-7 cells
-
Concentration:24.52 μM
-
Incubation Time:24 h
-
Result:Increased the percentage of cells at G0/G1 to 84.13 % in comparison to the control (61.09%).
Induced a lower reduction in the cell percentage of cells at S phase (30.56 %) than Doxorubicin (HY-15142A) (12.32 %).
Decreased population of cells at G2/M phase (3.55 %) than the control (9.27 %).
-
Cell Line:MCF-7 cells
-
Concentration:24.52 μM
-
Incubation Time:24 h
-
Result:Increased annexin-V positive apoptotic cells at the early and late apoptotic stages and necrosis percentage.
Significantly up-regulated the pro-apoptotic Bax expression level by 6.96 fold and down-regulated the anti-apoptotic Bcl-2 expression level by 0.23 fold.
Chemical Information
-
Molecular Weight 531.46
-
Formula C28H23BrN2O2S
-
SMILES
CC1=CC=C(C2=CSC3=NC(C4=CC=CC=C4)=C(C(OCC)=O)C(C5=CC=C(Br)C=C5)N32)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Topoisomerase II inhibitor 23 Related Classifications
HY-174404 Related Classifications
Powered by Bioz